Table 2.
No. | Population | No. of Subjects | Dose (mg) |
Dosage Form | Age (Years) | Weight (kg) |
Female Proportion | Ref. |
---|---|---|---|---|---|---|---|---|
IV | ||||||||
1 | Healthy | 9 | 2 | IV solution | 20−30 | 58−80 | 0 | [46] |
2 | Healthy | 8 | 5 | IV solution | Mean 28.3 | - | 0.33 | [47] |
3 | Healthy | 24 | 5 | IV solution | 18−45 | Mean 71.8 | 0.2 | [48] |
4 | Healthy | 20 | 7.5 | IV solution | Mean 28.8 | Mean 72.6 | 0 | [49] |
5 | Healthy | 9 | 1 | IV solution | 18−25 | 58−70 | 0.33 | [15] |
6 | Healthy | 1 | 10 | IV solution | 26−37 | 60−85 | 0.2 | [50] |
Oral | ||||||||
7 | Healthy | 11 | 2 | - | 19−35 | - | 0.27 | [51] |
8 | Healthy | 11 | 5 | - | 19−35 | - | 0.27 | [51] |
9 | Healthy | 48 | 10 | Tablets | 18−44 | 59.1−95 | 0 | [52] |
10 | Healthy | 11 | 10 | - | 19−35 | - | 0.27 | [51] |
11 | Healthy | 9 | 10 | Tablet | 18−25 | 58−70 | 0.33 | [15] |
Intranasal | ||||||||
12 | Healthy | 9 | 2 | Solution | 20−30 | 58–80 | 0 | [46] |
13 | Healthy | 8 | 5 | Supersaturated solution | Mean 28.3 | - | 0.33 | [47] |
14 | Healthy | 24 | 10 | Solution | 18−45 | Mean 71.8 | 0.2 | [48] |
15 | Healthy | 24 | 10 | Suspension | 18−45 | Mean 71.8 | 0.2 | [48] |
16 | Healthy | 8 | 10 | Supersaturated solution | Mean 28.3 | - | 0.33 | [47] |
17 | Healthy | 1 | 10 | Solution | 26−37 | 60−85 | 0.2 | [50] |
Rectal | ||||||||
18 | Healthy | 9 | 10 | Solution | 18−25 | 58−70 | 0.33 | [15] |
19 | Healthy | 9 | 10 | Suppository | 18−25 | 58−70 | 0.33 | [15] |
19 | Healthy | 20 | 15 | Gel | Mean 28.8 | Mean 173.9 | 0 | [49] |